{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:44:16Z","timestamp":1787312656490,"version":"build-2736575974"},"reference-count":127,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The outcome of multiple myeloma (MM) has significantly improved in the last few decades due to several factors such as new biological discoveries allowing to better stratify disease risk, development of more effective therapies and better management of side effects related to them. However, handling all these aspects requires an interdisciplinary approach involving multiple knowledge and collaboration of different specialists. The hematologist, faced with a patient with MM, must not only choose a treatment according to patient and disease characteristics but must also know when therapy needs to be started and how to monitor it during and after treatment. Moreover, he must deal not only with organ issues related to MM such as bone disease, renal failure or neurological disease but also with adverse events, often very serious, related to novel therapies, particularly new generation immunotherapies such as CAR T cell therapy and bispecific antibodies. In this review, we provide an overview on the newer MM diagnostic and monitoring strategies and on the main side effects of MM therapies, focusing on adverse events occurring during treatment with CAR T cells and bispecific antibodies.<\/jats:p>","DOI":"10.3390\/cancers16122263","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T04:21:28Z","timestamp":1718770888000},"page":"2263","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management"],"prefix":"10.3390","volume":"16","author":[{"given":"Sonia","family":"Mor\u00e8","sequence":"first","affiliation":[{"name":"Clinica di Ematologia Azienda Ospedaliero, Universitaria delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Corvatta","sequence":"additional","affiliation":[{"name":"U.O.C. Medicina, Ospedale Profili, 60044 Fabriano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina Maria","family":"Manieri","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia Azienda Ospedaliero, Universitaria delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Morsia","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia Azienda Ospedaliero, Universitaria delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2749-7347","authenticated-orcid":false,"given":"Massimo","family":"Offidani","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia Azienda Ospedaliero, Universitaria delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, Presenting Features and Outcome of Extramedullary Disease in Multiple Myeloma: A Longitudinal Study on 1003 Consecutive Patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO.23.01277","article-title":"Genomic Classification and Individualized Prognosis in Multiple Myeloma","volume":"42","author":"Maura","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/blood.2022017789","article-title":"A Phase 2 Clinical Trial of Combined BRAF\/MEK Inhibition for BRAFV600E-Mutated Multiple Myeloma","volume":"141","author":"Giesen","year":"2023","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood.2022017010","article-title":"Whole-Genome Analysis Identifies Novel Drivers and High-Risk Double-Hit Events in Relapsed\/Refractory Myeloma","volume":"141","author":"Samur","year":"2023","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and Management of Adverse Events during Treatment with Bispecific Antibodies and CAR T Cells in Multiple Myeloma: A Consensus Report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Laval, V., Lumbreras-Fern\u00e1ndez, B., Aguado-Bueno, B., and G\u00f3mez-Le\u00f3n, N. (2024). Imaging of Multiple Myeloma: Present and Future. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010264"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International Myeloma Working Group Consensus Recommendations on Imaging in Monoclonal Plasma Cell Disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41408-018-0124-1","article-title":"Recommendations for Acquisition, Interpretation and Reporting of Whole Body Low Dose CT in Patients with Multiple Myeloma and Other Plasma Cell Disorders: A Report of the IMWG Bone Working Group","volume":"8","author":"Moulopoulos","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1159\/000531461","article-title":"Photon Counting Detector Computed Tomography: A New Frontier of Myeloma Bone Disease Evaluation","volume":"146","author":"Cook","year":"2023","journal-title":"Acta Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1007\/s00330-022-09225-0","article-title":"Myeloma Bone Disease Imaging on a 1st-Generation Clinical Photon-Counting Detector CT vs. 2nd-Generation Dual-Source Dual-Energy CT","volume":"33","author":"Winkelmann","year":"2023","journal-title":"Eur. Radiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1053\/j.seminoncol.2022.01.007","article-title":"Modern Radiographic Imaging in Multiple Myeloma, What Is the Minimum Requirement?","volume":"49","author":"Mena","year":"2022","journal-title":"Semin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low Expression of Hexokinase-2 Is Associated with False-Negative FDG-Positron Emission Tomography in Multiple Myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3109\/10428194.2012.740559","article-title":"Challenges and Opportunities of Novel Imaging Techniques in Monoclonal Plasma Cell Disorders: Imaging \u201cEarly Myeloma\u201d","volume":"54","author":"Hillengass","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Torkian, P., Azadbakht, J., Andrea Bonaffini, P., Amini, B., and Chalian, M. (2022). Advanced Imaging in Multiple Myeloma: New Frontiers for MRI. Diagnostics, 12.","DOI":"10.3390\/diagnostics12092182"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e210048","DOI":"10.1148\/rycan.2021210048","article-title":"Prospective Evaluation of Whole-Body MRI versus FDG PET\/CT for Lesion Detection in Participants with Myeloma","volume":"3","author":"Messiou","year":"2021","journal-title":"Radiol. Imaging Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41408-020-0319-0","article-title":"The Role of Bone Marrow Biopsy in Patients with Plasma Cell Disorders: Should All Patients with a Monoclonal Protein Be Biopsied?","volume":"10","author":"Sidiqi","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1007\/s00330-021-08419-2","article-title":"Feasibility of Artificial Intelligence\u2013Supported Assessment of Bone Marrow Infiltration Using Dual-Energy Computed Tomography in Patients with Evidence of Monoclonal Protein\u2014A Retrospective Observational Study","volume":"32","author":"Fervers","year":"2022","journal-title":"Eur. Radiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2478\/raon-2024-0003","article-title":"Quantitative Assessment of Bone Marrow Infiltration and Characterization of Tumor Burden Using Dual-Layer Spectral CT in Patients with Multiple Myeloma","volume":"58","author":"Xiong","year":"2024","journal-title":"Radiol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101910","DOI":"10.1016\/j.eclinm.2023.101910","article-title":"SLiM CRAB Criteria Revisited: Temporal Trends in Prognosis of Patients with Smoldering Multiple Myeloma Who Meet the Definition of \u2019Biomarker-Defined Early Multiple Myeloma\u2019-a Systematic Review with Meta-Analysis","volume":"58","author":"Ludwig","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/s41375-022-01529-w","article-title":"Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio \u2265100","volume":"36","author":"Visram","year":"2022","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for Multiple Myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.3324\/haematol.2021.280566","article-title":"Heterogeneity in Long-Term Outcomes for Patients with Revised International Staging System Stage II, Newly Diagnosed Multiple Myeloma","volume":"108","author":"Schavgoulidze","year":"2023","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report within the HARMONY Project","volume":"40","author":"Cairns","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.18.00776","article-title":"Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma","volume":"37","author":"Perrot","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41408-023-00933-4","article-title":"Prognostic Impact of Translocation t(14;16) in Multiple Myeloma According to the Presence of Additional Genetic Lesions","volume":"13","author":"Schavgoulidze","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-024-00978-z","article-title":"Translocation t(14;16) in Multiple Myeloma: Gangster or Just Part of the Gang?","volume":"14","author":"Mian","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.2022017863","article-title":"Biallelic Deletion of 1p32 Defines Ultra-High-Risk Myeloma, but Monoallelic Del(1p32) Remains a Strong Prognostic Factor","volume":"141","author":"Schavgoulidze","year":"2023","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41408-019-0221-9","article-title":"Mutational Processes Contributing to the Development of Multiple Myeloma","volume":"9","author":"Hoang","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/s41375-024-02210-0","article-title":"Redefining High Risk Multiple Myeloma with an APOBEC\/Inflammation-Based Classifier","volume":"38","author":"Grasedieck","year":"2024","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.hoc.2023.12.008","article-title":"Approach to High-Risk Multiple Myeloma","volume":"38","author":"Chen","year":"2024","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_35","first-page":"890","article-title":"Impact of Extramedullary Disease in Patients with Newly Diagnosed Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Study from the Chronic Malignancies Working Party of the EBMT","volume":"103","author":"Gagelmann","year":"2018","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41375-024-02206-w","article-title":"Beyond the Marrow: Insights from Comprehensive next-Generation Sequencing of Extramedullary Multiple Myeloma Tumors","volume":"38","author":"Jelinek","year":"2024","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.21.01393","article-title":"High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma","volume":"40","author":"Bertamini","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating Tumor Cells for the Staging of Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma","volume":"40","author":"Cedena","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2023-186411","article-title":"Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)","volume":"142","author":"Termini","year":"2023","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2338604","DOI":"10.1080\/07853890.2024.2338604","article-title":"Circulating Plasma Cells as a Predictive Biomarker in Multiple Myeloma: An Updated Systematic Review and Meta-Analysis","volume":"56","author":"Li","year":"2024","journal-title":"Ann. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","article-title":"The Presence of Large Focal Lesions Is a Strong Independent Prognostic Factor in Multiple Myeloma","volume":"132","author":"Rasche","year":"2018","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s10916-024-02040-8","article-title":"3D CNN-Based Deep Learning Model-Based Explanatory Prognostication in Patients with Multiple Myeloma Using Whole-Body MRI","volume":"48","author":"Morita","year":"2024","journal-title":"J. Med. Syst."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1007\/s00259-023-06339-5","article-title":"Application of an Artificial Intelligence-Based Tool in [18F]FDG PET\/CT for the Assessment of Bone Marrow Involvement in Multiple Myeloma","volume":"50","author":"Sachpekidis","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/blood.2023021581","article-title":"A P53 Score Derived from TP53 CRISPR\/Cas9 HMCLs Predicts Survival and Reveals a Major Role of BAX in the Response to BH3 Mimetics","volume":"143","author":"Durand","year":"2024","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"107469","DOI":"10.1016\/j.leukres.2024.107469","article-title":"Expression of the Chemokine Receptor CCR1 Decreases Sensitivity to Bortezomib in Multiple Myeloma Cell Lines","volume":"139","author":"Zeissig","year":"2024","journal-title":"Leuk. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.3324\/haematol.2020.253526","article-title":"Expression of the Chemokine Receptor CCR1 Promotes the Dissemination of Multiple Myeloma Plasma Cells In Vivo","volume":"106","author":"Zeissig","year":"2021","journal-title":"Haematologica"},{"key":"ref_47","first-page":"1206","article-title":"Ribosomal Protein S3 Mediates Drug Resistance of Proteasome Inhibitor: Potential Therapeutic Application in Multiple Myeloma","volume":"109","author":"Chen","year":"2024","journal-title":"Haematologica"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"200771","DOI":"10.1016\/j.omton.2024.200771","article-title":"Targeting the Ribosome to Treat Multiple Myeloma","volume":"32","author":"Maclachlan","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s43018-023-00657-1","article-title":"Genomic and Immune Signatures Predict Clinical Outcome in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens","volume":"4","author":"Maura","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood-2023-182734","article-title":"Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients","volume":"142","author":"Agarwal","year":"2023","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Andreozzi, F., Dragani, M., Quivoron, C., Le Bras, F., Assi, T., Danu, A., Belhadj, K., Lazarovici, J., Cotteret, S., and Bernard, O.A. (2023). Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study. Cancers, 15.","DOI":"10.3390\/cancers15051508"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of Minimal Residual Disease with Superior Survival Outcomes in Patients with Multiple Myeloma: A Meta-Analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD Detection in Multiple Myeloma: Comparison between MSKCC 10-Color Single-Tube and EuroFlow 8-Color 2-Tube Methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for Highly Sensitive and Standardized Detection of Minimal Residual Disease in Multiple Myeloma","volume":"31","author":"Paiva","year":"2017","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Szalat, R., Anderson, K., and Munshi, N. (2024). Role of Minimal Residual Disease Assessment in Multiple Myeloma. Haematologica.","DOI":"10.3324\/haematol.2023.284662"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"102016","DOI":"10.1016\/j.eclinm.2023.102016","article-title":"Prospective Evaluation of Minimal Residual Disease in the Phase II FORTE Trial: A Head-to-Head Comparison between Multiparameter Flow Cytometry and next-Generation Sequencing","volume":"60","author":"Oliva","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A Large Meta-Analysis Establishes the Role of MRD Negativity in Long-Term Survival Outcomes in Patients with Multiple Myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2021011101","article-title":"Prognostic Value of Minimal Residual Disease Negativity in Myeloma: Combined Analysis of POLLUX, CASTOR, ALCYONE, and MAIA","volume":"139","author":"Cavo","year":"2022","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma and the Impact of Daratumumab in MAIA and ALCYONE","volume":"139","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood.2023022080","article-title":"Predictors of Unsustained Measurable Residual Disease Negativity in Patients with Multiple Myeloma","volume":"143","author":"Bertuglia","year":"2024","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2023022083","article-title":"Predictors of Unsustained Measurable Residual Disease Negativity in Transplant-Eligible Patients with Multiple Myeloma","volume":"143","author":"Guerrero","year":"2024","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2023-185980","article-title":"Clinical Significance of Measurable Residual Disease (MRD) in Relapsed\/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Chimeric Antigen Receptor (CAR) T Cells and T-Cell Engagers (TCE)","volume":"142","author":"Zabaleta","year":"2023","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood-2023-186916","article-title":"Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)","volume":"142","author":"Gonzalez","year":"2023","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/clinchem\/hvz041","article-title":"Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins","volume":"66","author":"Zajec","year":"2020","journal-title":"Clin. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-022-00624-6","article-title":"Mass-Fix Better Predicts for PFS and OS than Standard Methods among Multiple Myeloma Patients Participating on the STAMINA Trial (BMT CTN 0702 \/07LT)","volume":"12","author":"Dispenzieri","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","article-title":"Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma","volume":"13","author":"Mai","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1182\/blood-2023-189850","article-title":"Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)","volume":"142","author":"Kubicki","year":"2023","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Kubicki, T., Dytfeld, D., Barnidge, D.R., Sakrikar, D., Przyby\u0142owicz-Chalecka, A., Jamroziak, K., Robak, P., Czyz, J., Tyczynska, A., and Druzd-Sitek, A.A. Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma. Blood, 2024. in press.","DOI":"10.1182\/blood.2024024041"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic Relevance of 18-F FDG PET\/CT in Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.eclinm.2023.102017","article-title":"Impact of Minimal Residual Disease Standardised Assessment by FDG-PET\/CT in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Enrolled in the Imaging Sub-Study of the FORTE Trial","volume":"60","author":"Zamagni","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1148\/radiol.2019181949","article-title":"Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS)","volume":"291","author":"Messiou","year":"2019","journal-title":"Radiology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"E230","DOI":"10.1002\/ajh.26995","article-title":"Predictive Role of Sustained Imaging MRD Negativity Assessed by Diffusion-Weighted Whole-Body MRI in Multiple Myeloma","volume":"98","author":"Belotti","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab before and after Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-Label, Phase 3 Study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): Final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma (MASTER): Final Report of the Multicentre, Single-Arm, Phase 2 Trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023023597","article-title":"Daratumumab Carfilzomib Lenalidomide and Dexamethasone with Tandem Transplant in High-Risk Newly Diagnosed Myeloma","volume":"143","author":"Touzeau","year":"2024","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy for Newly Diagnosed, Transplantation-Eligible Patients with Multiple Myeloma (GMMG-HD7): Part 1 of an Open-Label, Multicentre, Randomised, Active-Controlled, Phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients","volume":"142","author":"Gay","year":"2023","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/hematology.2023000435","article-title":"Managing Side Effects: Guidance for Use of Immunotherapies in Multiple Myeloma","volume":"2023","author":"Liang","year":"2023","journal-title":"Hematology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2022-162440","article-title":"Efficacy and Safety of Elranatamab in Patients with Relapsed\/Refractory Multiple Myeloma Na\u00efve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study","volume":"140","author":"Bahlis","year":"2022","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"10140","DOI":"10.1182\/blood-2022-159969","article-title":"Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed\/Refractory Multiple Myeloma: A Phase 1\/2 First-in-Human Study","volume":"140","author":"Bumma","year":"2022","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/blood-2022-159009","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study","volume":"140","author":"Wong","year":"2022","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen \u00d7 CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"40","author":"Shah","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2023-181936","article-title":"Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed\/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial","volume":"142","author":"Rajeeve","year":"2023","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of Chimeric Antigen Receptor T Cells: Recognition and Management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"814548","DOI":"10.3389\/fimmu.2022.814548","article-title":"Correlation of Cytokine Release Syndrome with Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients with Relapsed or Refractory Multiple Myeloma","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e75458a8","DOI":"10.1097\/01.HS9.0000970688.75458.a8","article-title":"Tocilizumab pre-treatment significantly reduces the incidence of cytokine release syndrome in patients with relapsed\/refractory multiple myeloma (RRMM) who received cevostamab","volume":"7","author":"Mateos","year":"2023","journal-title":"HemaSphere"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41408-023-00963-y","article-title":"Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab: A Single-Center Experience","volume":"13","author":"Scott","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1200\/JCO.2023.41.16_suppl.8033","article-title":"Evaluation of Prophylactic Tocilizumab (Toci) for the Reduction of Cytokine Release Syndrome (CRS) to Inform the Management of Patients (Pts) Treated with Teclistamab in MajesTEC-1","volume":"41","author":"Garfall","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1182\/blood-2023-189878","article-title":"Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration","volume":"142","author":"Marin","year":"2023","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1182\/blood-2023-187086","article-title":"Tocilizumab Prophylaxis for Patients Treated with Teclistamab: A Single-Center Experience","volume":"142","author":"Kowalski","year":"2023","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Kr\u00f6ger, N., Gribben, J., Chabannon, C., Yakoub-Agha, I., and Einsele, H. (2022). Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). The EBMT\/EHA CAR-T Cell Handbook, Springer.","DOI":"10.1007\/978-3-030-94353-0"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 Final Results: Phase 1b\/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients with Relapsed\/Refractory Multiple Myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"6937","DOI":"10.1182\/blood-2023-188090","article-title":"Incidence of Parkinsonism As a Complication of Anti-BCMA CAR-T Cell Therapy in Multiple Myeloma","volume":"142","author":"Singh","year":"2023","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2023.41.16_suppl.8006","article-title":"LINKER-MM1 Study: Linvoseltamab (REGN5458) in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"41","author":"Lee","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1182\/bloodadvances.2021005020","article-title":"Macrophage Activation Syndrome-like (MAS-L) Manifestations Following BCMA-Directed CAR T Cells in Multiple Myeloma","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Adv."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jaad.2023.08.094","article-title":"Dermatological Toxicities Induced by T-Cell-Redirecting G Protein-Coupled Receptor Family C Class 5 Member D Bispecific Antibody Talquetamab","volume":"90","author":"Lery","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early Mortality after Diagnosis of Multiple Myeloma: Analysis of Patients Entered onto the United Kingdom Medical Research Council Trials between 1980 and 2002\u2014Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple Myeloma and Infections: A Population-Based Study on 9253 Multiple Myeloma Patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-022-00652-2","article-title":"A Simple Score to Predict Early Severe Infections in Patients with Newly Diagnosed Multiple Myeloma","volume":"12","author":"Encinas","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41375-018-0133-x","article-title":"A Predictive Model for Risk of Early Grade \u22653 Infection in Patients with Multiple Myeloma Not Eligible for Transplant: Analysis of the FIRST Trial","volume":"32","author":"Dumontet","year":"2018","journal-title":"Leukemia"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1111\/bjh.16735","article-title":"Infection Risk with Carfilzomib in Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","volume":"190","author":"Wongsaengsak","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"ofac574","DOI":"10.1093\/ofid\/ofac574","article-title":"Cumulative Incidence and Relative Risk of Infection in Patients with Multiple Myeloma Treated with Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-Analysis","volume":"9","author":"Vassilopoulos","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.15433","article-title":"Infectious and Immunological Sequelae of Daratumumab in Multiple Myeloma","volume":"185","author":"Johnsrud","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of Daratumumab on Natural Killer Cells and Impact on Clinical Outcomes in Relapsed or Refractory Multiple Myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"103623","DOI":"10.1016\/j.critrevonc.2022.103623","article-title":"Management of Infectious Risk of Daratumumab Therapy in Multiple Myeloma: A Consensus-Based Position Paper from an Ad Hoc Italian Expert Panel","volume":"172","author":"Girmenia","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral Immune Reconstitution after Anti-BCMA CAR T-Cell Therapy in Relapsed\/Refractory Multiple Myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b\/2 Open-Label Study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2023-180013","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) \u00d7 CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study","volume":"142","author":"Bar","year":"2023","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv."},{"key":"ref_121","first-page":"764","article-title":"Characteristics and Incidence of Infections in Patients with Multiple Myeloma Treated by Bispecific Antibodies: A National Retrospective Study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious Complications in Patients with Relapsed Refractory Multiple Myeloma after BCMA CAR T-Cell Therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early Cytopenias and Infections after Standard of Care Idecabtagene Vicleucel in Relapsed or Refractory Multiple Myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"304.e1","DOI":"10.1016\/j.jtct.2022.03.005","article-title":"Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma","volume":"28","author":"Josyula","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1182\/blood-2022-167834","article-title":"Infectious Complications of Bispecific Antibody Therapy in Patients with Multiple Myeloma","volume":"140","author":"Sim","year":"2022","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2023-179413","article-title":"A Comparative Analysis of Infectious Complications in Patients with Multiple Myeloma Treated with BCMA-Targeted Bispecific Antibodies and CAR T-Cell Therapy","volume":"142","author":"Nath","year":"2023","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/12\/2263\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:00:50Z","timestamp":1760108450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/12\/2263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":127,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["cancers16122263"],"URL":"https:\/\/doi.org\/10.3390\/cancers16122263","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]}}}